Such discrepancies serve to highlight the problematic heterogeneity (e.g. tumour downstaging or tumour regression) encountered in this field when attempting to draw conclusions, thus explaining why HIF-1α is, to date, not used as a clinically useful prognostic biomarker in RC. Here, HIF1A is linked to neoplasm.